CTT Pharma Grant Updates

(TheNewswire)

Tampa, Florida, United States – TheNewswire – June 10, 2025 – CTT Pharmaceutical Holdings, Inc.(OTCQB:CTTH) is awaiting information on our grant with Johns HopkinsUniversity for clinical trials with the NIH utilizing our patentedtechnology for a smoking cessation product. Additionally, we are notaware of any delays for this grant with the NIH.

CTT has spoken with the program officer at the NSF in regards to thereviewers comments which were very positive about our patentedtechnology. CTT will make the necessary changes and will add one ofits scientists who has won multiple grant awards as the PrincipalInvestigator(PI) for a resubmission . This resubmission will happen onor before July 2, 2025 and CTT will keep shareholders updated on thisgrant.

Additional Corporate Updates for CTTPharma:

• CTT will file a SBA loan in the next week to raise capital formanufacturing.

• CTT's CEO is in conversations with several companies for utilizing ourtechnology.

• Our scientist is in the process of applying for a new grant utilizingan active ingredient not used in previous grants.

• Our patent office in the process of strengthening our patents in theUnited States and Europe.

• The PCAOB audit firm that CTT hired successfully completed an auditfor 2024. CTT now has 3 years of PCAOB audits completed.

• The CEO will be doing a shareholder conference call and will informinvestors in the near future.

• Uplisted to the OTCQB in March 2025.

CTT Pharma – 813-606-0060

Copyright (c) 2025 TheNewswire - All rights reserved.